In Q1 FY2026 (ended March 31, 2026), Royalty Pharma plc reported revenue of $630.6 million, up 11.0% year-over-year. Net income rose 23.1% to $294.7 million, with diluted EPS of $0.67, a 21.8% increase. Operating income grew 5.4% to $563.0 million. The company had $586.4 million in cash and $8.96 billion in long-term debt.
•Revenue increased 11.0% YoY to $630.6 million.
•Net income grew 23.1% to $294.7 million; diluted EPS up 21.8% to $0.67.
•Operating income rose 5.4% to $563.0 million.
•Cash balance of $586.4 million; long-term debt of $8.96 billion.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Royalty Pharma is a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
The company has R&D funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. Founded in 1996, the company is based in New York, New York.
Royalty Pharma is a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. The company acquires royalties on marketed therapies and development-stage product candidates, providing capital to biopharmaceutical companies in exchange for a share of future sales. Its portfolio includes royalties on approximately 35 marketed therapies and 20 development-stage product candidates. These cover a wide range of therapeutic areas, including rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. Additionally, Royalty Pharma has an R&D funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is headquartered in New York, New York.
On which stock exchange is Royalty Pharma (RPRX) listed and what is its currency?
Royalty Pharma plc, trading under the ticker symbol RPRX, is listed on the Nasdaq Global Select Market (NasdaqGS) in the United States. The company's financial reporting and stock trading are conducted in US Dollars (USD). As a Nasdaq-listed company, Royalty Pharma is subject to the exchange's listing requirements and regulatory oversight by the U.S. Securities and Exchange Commission. Investors can buy and sell RPRX shares through brokerage accounts that have access to the Nasdaq exchange.
What sector and industry does Royalty Pharma (RPRX) belong to?
Royalty Pharma operates in the Healthcare sector and is classified under the Biotechnology industry. As a healthcare company, it focuses on funding innovation and acquiring royalties in the biopharmaceutical space. The biotechnology industry involves the use of biological processes to develop therapies and medical products. Royalty Pharma's role is unique within this industry because it does not conduct its own research and development; instead, it provides capital to other biopharmaceutical companies and shares in the financial success of their approved drugs and product candidates. This business model allows it to participate in the upside of multiple therapies across various therapeutic areas without bearing the full risk of drug development.
Where is Royalty Pharma (RPRX) headquartered and what markets does it serve?
Royalty Pharma is headquartered in New York, New York, United States. The company primarily serves the U.S. biopharmaceutical market, as indicated by its description summary stating it operates in the United States. Its portfolio includes royalties on therapies that address a broad range of diseases, including rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. While the company is based in the U.S., its royalty interests may involve products marketed globally, as many biopharmaceutical companies have international reach. However, the available data does not specify operations in other countries. The company was founded in 1996 and has since built a substantial portfolio of biopharmaceutical royalties.
How does Royalty Pharma (RPRX) generate revenue?
Royalty Pharma generates revenue primarily by acquiring royalties on biopharmaceutical products. The company purchases existing royalties from drug developers or provides funding for research and development in exchange for a percentage of future product sales. Its portfolio includes royalties on approximately 35 marketed therapies and 20 development-stage product candidates. When these therapies generate sales, Royalty Pharma receives a contractual share of those revenues. The company's business model is capital-intensive, requiring upfront payments to secure royalty interests, but it offers diversified exposure to multiple drugs and therapeutic areas. Additionally, Royalty Pharma has an R&D funding collaboration for JNJ-4804, an investigational autoimmune disease medicine, which may yield future royalties if the product is approved and commercialized.